Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nutex HealthFRA:5LF +3.77%57 EPS without NRI is €21.68 as of Jun. 2026. GuruFocus rates FRA:5LF with a GF Score™ of 57/100 and a GF Value™ of €70.29 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Nutex Health ranks worse than 197628.26% on this metric.
Nutex Health's earnings per share without non-recurring items for the
three
months ended in Jun. 2026 was €8.14.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was €21.68.
During the past 12 months, Nutex Health's average earnings per share (NRI) Growth Rate was 129.60% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Nutex Health's EPS without NRI or its related term are showing as below:
During the past 7 years, Nutex Health's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -29.60% per year. The lowest was -29.60% per year. And the median was -29.60% per year.
FRA:5LF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 11 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Nutex Health's EPS (Diluted) for the
three
months ended in Jun. 2026 was €8.14.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €21.68.
Nutex Health's EPS (Basic) for the
three
months ended in Jun. 2026 was €8.32.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €22.44.
Nutex Health (FRA:5LF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Nutex Health EPS without NRI Related Terms
Nutex Health EPS without NRI Historical Data
* Premium members only.
The historical data trend for Nutex Health's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LF vs USPH, AMN, GMRS: EPS without NRI Comparison
For the Medical Care Facilities subindustry, Nutex Health's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutex Health PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nutex Health's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Nutex Health's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutex Health (FRA:5LF) has a EPS without NRI of €21.68 as of Jun. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Nutex Health and its competitors. According to the industry distribution chart, Nutex Health ranks #999999 out of 506 companies in the Healthcare Providers & Services industry.
Is Nutex Health's EPS without NRI too high?
Nutex Health's current EPS without NRI is €21.68. Based on the distribution chart, Nutex Health ranks #999999 out of 506 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Nutex Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nutex Health's EPS without NRI compare to USPH and AMN?
According to the Healthcare Providers & Services industry distribution chart, Nutex Health ranks #999999 out of 506 companies for EPS without NRI. This places Nutex Health in the lower half of its industry. The industry median EPS without NRI is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.00, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Nutex Health and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutex Health's current EPS without NRI is €21.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutex Health stock overvalued right now?
Based on GuruFocus' analysis, Nutex Health (FRA:5LF) is currently considered Significantly Overvalued. The stock's GF Value™ is €70.29, compared to a current price of €165.00 — trading 134.7% above its estimated fair value. The current EPS without NRI is €21.68. Nutex Health's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Nutex Health (FRA:5LF), the current EPS without NRI is €21.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nutex Health (FRA:5LF) Overvalued in 2026?
Based on GuruFocus' analysis, Nutex Health stock appears to be overvalued.
The current stock price of €165.00 is trading 134.7% above its estimated GF Value™ of €70.29.
GuruFocus considers Nutex Health to be Significantly Overvalued.
Key valuation signals for FRA:5LF:
EPS without NRI: €21.68
GF Value™: €70.29 vs. price of €165.00 (134.7% above fair value)
No single metric tells the full story. See the FRA:5LF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
57GF Score
Get the complete analysis for FRA:5LF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LF has been successfully added to your 
